Freeport McMoRan's (FCX +2.7%) planned acquisition of Plains Exploration (PXP) likely will close in June despite objections, Morgan Stanley predicts as it maintains an Outperform rating on the shares. Long-term FCX shareholders should be rewarded with strong growth through 2015 and lower political uncertainty, the firm says, adding that copper inventories are starting to decline. [View news story]
I predict that FCX will eventually prove all of the nay-sayers wrong with this acquisition. The diversification will prove to be good for the company and the stock. Just a feeling I have!
It's my opinion that a CVX stock split is, by no means, a sure thing. In recent years, more and more companies have allowed their stock price to rise to unusually high levels. (Consider IBM, GOOG, MA, AAPL, PCLN). Contributing to companies' reluctance to do a stock split is the fact that splits are quite expensive for a company. First there are substantial administrative costs. And, second, if the company is repurchasing their shares, buying twice as many shares on the open market can also be substantially more expensive. That said, I personally would welcome a stock split. Although most analysts say that a split does not improve a stock's future performance, I don't completely agree with that. Stocks I have had that have split have tended to do quite well after the split. Would they have done similarly well without the split? Perhaps. If anything, a split does make the stock easier to buy for more people. That is usually a plus for a stock's reputation as an investment.
I don't really understand (or don't take the time to understand) all the analysis above. All I know is that my CVX Drip, in which I've invested steadily (but only in small added increments) since 1992, has doubled in value over that period of time. That doubling includes the reinvested dividends. Also, I am now enjoying the results of a very steady and consistent year to year increase in dividends, resulting in a quarterly dividend income now of over $3000 each quarter. By any comparison, CVX has treated me well, in comparison to most of the stocks in which my friends have invested. I have increased my investment in CVX whenever its share price is low; I decrease it when it looks a bit pricey. I will continue to invest in CVX most months and I think the stock has a great future of continued growth, based on all market indicators.
Peter... Re CVX, I fully agree. I've had a DRIP with CVX since 1992 and have stayed with it through ups an downs. The future vibes look to be extremely positive for this company. I'm staying with it and, along the way, reinvesting my over $3000 a quarter dividends. Steady investing in a DRIP, with the right stocks, of course, is a great way to build value over time.
The big U.S. banks are considering defying the Fed and announcing capital return plans shortly after stress tests are released this afternoon, reports Bloomberg. The Fed wants the lenders to wait another week, but bank lawyers worry the plans will leak out. It's under discussion, JPM CFO Lake told an investor conference (transcript) Tuesday. XLF +0.6%. [View news story]
Amen....you can lay the past problems of the banks at the feet of people like Barney Frank and Chris Dodd. Bad loans, mortgages that should never have been granted and similar actions -- most pressured by do-good politicians who believed that EVERYONE should own a house, regardless of the ability to pay for it -- these are what knocked the banks down. Unfortunately, some banks are again granting mortgages to those with questionable ability to pay and far too small down payments. On the other hand, the return of capital to stockholders has never done anything to undermine the banks and their stability.
Altria (MO) declares $0.44/share quarterly dividend, in line with previous. Forward yield 5.29%. For shareholders of record Dec. 26. Payable Jan. 10. Ex-div date Dec. 21. (PR) [View news story]
Altria (MO) declares $0.44/share quarterly dividend, in line with previous. Forward yield 5.29%. For shareholders of record Dec. 26. Payable Jan. 10. Ex-div date Dec. 21. (PR) [View news story]
Art...you took the words out of my mouth! MO was supposedly "dead" years ago. Not only does it keep paying (and modestly increasing) the dividend, this year has been quite good for share value growth too.
The right-to-work issue in Michigan isn't going unnoticed by labor unions. UAW President Bob King was at the state's Capitol building leading a protest against legislation that would allows workers to opt out of unions and not pay dues. The state House passed the measure yesterday by 58-42, sending it along to the Senate. Though the Big Three are deathly quiet on the issue, it wouldn't be a stretch to imagine weakened union laws in Michigan could help bottom lines. [View news story]
Sure wish I could find out how to pay no taxes on my dividends. You must be from another country. Dividends are always fully taxable in the USA, both at the corporate level and again at the individual taxpayer level. I suggest you brush up on your understanding of the tax code.
The right-to-work issue in Michigan isn't going unnoticed by labor unions. UAW President Bob King was at the state's Capitol building leading a protest against legislation that would allows workers to opt out of unions and not pay dues. The state House passed the measure yesterday by 58-42, sending it along to the Senate. Though the Big Three are deathly quiet on the issue, it wouldn't be a stretch to imagine weakened union laws in Michigan could help bottom lines. [View news story]
It is long past time that unions realize that they need to significantly change if they are to survive. Forced membership, just because you happen to have a particular trade, or work in a particular industry is completely out of fashion with a majority of the American public. Hence, the low level of acceptance unions now enjoy. Even more, unions need to change, reduce, and even get rid of their antiquated and destructive work rules. It simply isn't appropriate to require three union members (each from a different union) to change a light switch. Sounds ridiculous, but that's an example from real life (and from my work office).
Las Vegas Sands (LVS) declares special dividend of $2.75/share. Forward yield %. For shareholders of record Dec 10. Payable Dec 18. Ex-div date Dec 06. Shares +4.5% AH. (PR) [View news story]
Just adding another "way to go!" . I think we all like this!
Wells Fargo (WFC) declares $0.22/share quarterly dividend, in line with previous. Forward yield 2.60%. For shareholders of record Nov 09. Payable Dec 01. Ex-div date Nov 07. (PR) [View news story]
It would be interesting to know if, and when, Wells' dividend will again get back to the .34 a share that investors enjoyed in late 2008 and early 2009. Is it government regulations that are preventing a gradual increase in the dividend, or is it simply a result of earnings that do not support a dividend increase at this point in time? I'd be interested in knowing if anyone has information about this issue.
Shares of Amarin (AMRN -11.8%) and Horizon Pharma (HZNP -17.4%) sank after each received FDA approval of key drugs. Buying the rumor and selling the news? In the case of AMRN's Vascepa, investors are still waiting for New Chemical Entity status to make sure there isn’t a generic competitor. For HZNP, investors may doubt its ability to market its Rayos rheumatoid arthritis treatment. [View news story]
Not totally luck, but admittedly luck entered in. Putting in the sell order was a calculated decision and action. Had I not taken that action, it would have been a loss. You win some, you lose some. This time I was lucky enough to win. Plus, my action paid off.
Shares of Amarin (AMRN -11.8%) and Horizon Pharma (HZNP -17.4%) sank after each received FDA approval of key drugs. Buying the rumor and selling the news? In the case of AMRN's Vascepa, investors are still waiting for New Chemical Entity status to make sure there isn’t a generic competitor. For HZNP, investors may doubt its ability to market its Rayos rheumatoid arthritis treatment. [View news story]
Based on a recommendation I saw on Seeking Alpha, I put in a sell order last night for when the market opened (at the market price). It was a great move. My shares sold at the highest point, and then it was downhill for most of the day. However, I'm thinking about buying shares again in anticipation of NCE status and a potential buyout by a larger suitor. I still haven't made up my mind about doing that. Takes some balls to do that lol. Thanks to a Seeking Alpha contributor for helping me think through what to do on this one. My decision was right this time!
Freeport McMoRan's (FCX +2.7%) planned acquisition of Plains Exploration (PXP) likely will close in June despite objections, Morgan Stanley predicts as it maintains an Outperform rating on the shares. Long-term FCX shareholders should be rewarded with strong growth through 2015 and lower political uncertainty, the firm says, adding that copper inventories are starting to decline. [View news story]
Chevron Corporation Dividend Stock Analysis [View article]
Chevron Corporation Dividend Stock Analysis [View article]
Chevron Corporation Dividend Stock Analysis [View article]
Morgan Stanley selects 20 stocks for the long term, based on "competitive advantages, business model, pricing power, cost efficiency and growth": AMZN, AMT, BLK, CPN, CP, CVX, COST, EL, GILD, HON, JPM, LTD, MON, NWSA, PM, RPM, SBUX, SYMC, TMO, WMB. [View news story]
The big U.S. banks are considering defying the Fed and announcing capital return plans shortly after stress tests are released this afternoon, reports Bloomberg. The Fed wants the lenders to wait another week, but bank lawyers worry the plans will leak out. It's under discussion, JPM CFO Lake told an investor conference (transcript) Tuesday. XLF +0.6%. [View news story]
Altria (MO) declares $0.44/share quarterly dividend, in line with previous. Forward yield 5.29%. For shareholders of record Dec. 26. Payable Jan. 10. Ex-div date Dec. 21. (PR) [View news story]
Altria (MO) declares $0.44/share quarterly dividend, in line with previous. Forward yield 5.29%. For shareholders of record Dec. 26. Payable Jan. 10. Ex-div date Dec. 21. (PR) [View news story]
The right-to-work issue in Michigan isn't going unnoticed by labor unions. UAW President Bob King was at the state's Capitol building leading a protest against legislation that would allows workers to opt out of unions and not pay dues. The state House passed the measure yesterday by 58-42, sending it along to the Senate. Though the Big Three are deathly quiet on the issue, it wouldn't be a stretch to imagine weakened union laws in Michigan could help bottom lines. [View news story]
The right-to-work issue in Michigan isn't going unnoticed by labor unions. UAW President Bob King was at the state's Capitol building leading a protest against legislation that would allows workers to opt out of unions and not pay dues. The state House passed the measure yesterday by 58-42, sending it along to the Senate. Though the Big Three are deathly quiet on the issue, it wouldn't be a stretch to imagine weakened union laws in Michigan could help bottom lines. [View news story]
Las Vegas Sands (LVS) declares special dividend of $2.75/share. Forward yield %. For shareholders of record Dec 10. Payable Dec 18. Ex-div date Dec 06. Shares +4.5% AH. (PR) [View news story]
Wells Fargo (WFC) declares $0.22/share quarterly dividend, in line with previous. Forward yield 2.60%. For shareholders of record Nov 09. Payable Dec 01. Ex-div date Nov 07. (PR) [View news story]
Altria Posts A Fantastic Second Quarter [View article]
Shares of Amarin (AMRN -11.8%) and Horizon Pharma (HZNP -17.4%) sank after each received FDA approval of key drugs. Buying the rumor and selling the news? In the case of AMRN's Vascepa, investors are still waiting for New Chemical Entity status to make sure there isn’t a generic competitor. For HZNP, investors may doubt its ability to market its Rayos rheumatoid arthritis treatment. [View news story]
Shares of Amarin (AMRN -11.8%) and Horizon Pharma (HZNP -17.4%) sank after each received FDA approval of key drugs. Buying the rumor and selling the news? In the case of AMRN's Vascepa, investors are still waiting for New Chemical Entity status to make sure there isn’t a generic competitor. For HZNP, investors may doubt its ability to market its Rayos rheumatoid arthritis treatment. [View news story]